Your browser doesn't support javascript.
loading
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
El-Madani, Mévidette; Colomban, Olivier; Tod, Michel; Maillet, Denis; Peron, Julien; Rodriguez-Lafrasse, Claire; Badary, Osama A; Valette, Pierre-Jean; Lefort, Thibaud; Cassier, Philippe; El-Shenawy, Siham M; El-Demerdash, Ebtehal; Hommel-Fontaine, Juliette; Guitton, Jerome; Gagnieu, Marie-Claude; Ibrahim, Bassant Mm; Barrois, Catherine; Freyer, Gilles; You, Benoit.
Affiliation
  • El-Madani M; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
  • Colomban O; National Research Centre, Pharmacology Department, Cairo, Egypt.
  • Tod M; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
  • Maillet D; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
  • Peron J; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Lyon, France.
  • Rodriguez-Lafrasse C; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Lyon, France.
  • Badary OA; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
  • Valette PJ; Biochemistry & molecular biology department; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.
  • Lefort T; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
  • Cassier P; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
  • El-Shenawy SM; Radiology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.
  • El-Demerdash E; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
  • Hommel-Fontaine J; Radiology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.
  • Guitton J; Phase 1 trial Unit, Centre Léon Bérard, Lyon, France.
  • Gagnieu MC; National Research Centre, Pharmacology Department, Cairo, Egypt.
  • Ibrahim BM; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
  • Barrois C; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
  • Freyer G; Pathology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.
  • You B; Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.
Future Oncol ; 13(8): 679-693, 2017 Apr.
Article in En | MEDLINE | ID: mdl-28076966
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Antineoplastic Combined Chemotherapy Protocols / Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Language: En Journal: Future Oncol Year: 2017 Type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Antineoplastic Combined Chemotherapy Protocols / Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Language: En Journal: Future Oncol Year: 2017 Type: Article Affiliation country: France